Achmea Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Achmea Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-944	Closed	-$258K	–	547
2019 Q3	$258K	Hold	944	–	–	0.01%	475
2019 Q2	$504K	Hold	944	–	–	0.02%	443
2019 Q1	$476K	Hold	944	–	–	0.02%	393
2018 Q4	$465K	Hold	944	–	–	0.02%	389
2018 Q3	$862K	Hold	944	–	–	0.03%	377
2018 Q2	$691K	Buy	+944	New	+$1.09M	0.02%	409

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Achmea Investment Management's NKTR Position: Q4 2019 in Review

Achmea Investment Management sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 944 shares — an estimated $258K sold.

Achmea Investment Management first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $862K in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

Achmea Investment Management reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
Achmea Investment Management sold 944 Nektar Therapeutics shares in Q4 2019, an estimated $258K.
Achmea Investment Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
Achmea Investment Management's Nektar Therapeutics position peaked at $862K in Q3 2018.
281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Achmea Investment Management's 13F filing for Q4 2019, filed 10 Feb 2020.